Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results.

Komatsu T, Oizumi Y, Kunieda E, Tamai Y, Akiba T, Kogawa A.

Oncol Lett. 2011 Sep 1;2(5):855-860. Epub 2011 Jul 6.

2.

Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer.

Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, Makimoto T, Ishihara S, Saito R, Mori M.

Oncology. 1999;57(2):143-8.

PMID:
10461062
3.

Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.

Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T.

Lung Cancer. 2000 Mar;27(3):159-67.

PMID:
10699689
4.

Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.

Huang Z, Xu D, Zhang F, Ying Y, Song L.

Clin Transl Oncol. 2016 Oct;18(10):1019-25. doi: 10.1007/s12094-015-1479-4. Epub 2016 Feb 17.

PMID:
26886220
5.

Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?

Hirose T, Okuda K, Yamaoka T, Ishida K, Kusumoto S, Sugiyama T, Shirai T, Ohnshi T, Ohmori T, Adachi M.

Lung Cancer. 2011 Feb;71(2):224-8. doi: 10.1016/j.lungcan.2010.05.004.

PMID:
20537424
6.

Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.

Winther-Larsen A, Hoffmann L, Moeller DS, Khalil AA, Knap MM.

Acta Oncol. 2015;54(9):1574-81. doi: 10.3109/0284186X.2015.1062135. Epub 2015 Jul 23.

PMID:
26203924
7.

Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response.

Fujii M, Hotta K, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M, Kiura K.

Lung Cancer. 2012 Oct;78(1):107-11. doi: 10.1016/j.lungcan.2012.07.001. Epub 2012 Jul 31.

PMID:
22858447
8.

Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?

Akagunduz OO, Savas R, Yalman D, Kocacelebi K, Esassolak M.

Nucl Med Biol. 2015 Nov;42(11):899-904. doi: 10.1016/j.nucmedbio.2015.06.007. Epub 2015 Jun 22.

PMID:
26275933
9.

Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy.

Perez CA, Grigsby PW, Castro-Vita H, Lockett MA.

Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88.

PMID:
7635767
10.

Predictive factors in radiotherapy for non-small cell lung cancer: present status.

Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P.

Lung Cancer. 2001 Jan;31(1):43-56. Review.

PMID:
11162866
11.

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.

Klasa RJ, Murray N, Coldman AJ.

J Clin Oncol. 1991 Mar;9(3):499-508.

PMID:
1847968
12.

The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer.

Chen M, Jiang GL, Fu XL, Wang LJ, Qian H, Chen GY, Zhao S, Liu TF.

Lung Cancer. 2000 Apr;28(1):11-9.

PMID:
10704704
13.

Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis.

Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, Grimfors G, Björkholm M.

Haematologica. 2003 Apr;88(4):438-44.

14.

Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.

Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E 3rd.

Biol Blood Marrow Transplant. 2002;8(6):326-33.

PMID:
12108918
15.

Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis.

Niho S, Kubota K, Yoh K, Goto K, Ohmatsu H, Nihei K, Ohe Y, Nishiwaki Y.

J Thorac Oncol. 2011 Apr;6(4):796-800. doi: 10.1097/JTO.0b013e318208ec77.

16.

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy.

Manapov F, Niyazi M, Gerum S, Roengvoraphoj O, Eze C, Li M, Hildebrandt G, Fietkau R, Klautke G, Belka C.

BMC Cancer. 2016 Mar 14;16:216. doi: 10.1186/s12885-016-2245-x.

17.

Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.

Fauci JM, Whitworth JM, Schneider KE, Subramaniam A, Zhang B, Frederick PJ, Kilgore LC, Straughn JM Jr.

Gynecol Oncol. 2011 Sep;122(3):532-5. doi: 10.1016/j.ygyno.2011.05.023. Epub 2011 Jun 11.

PMID:
21658751
18.

Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer.

Han D, Qin Q, Hao S, Huang W, Wei Y, Zhang Z, Wang Z, Li B.

Radiat Oncol. 2014 Dec 11;9:280. doi: 10.1186/s13014-014-0280-9.

19.

Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.

Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N.

Clin Cancer Res. 1997 Jan;3(1):123-7.

20.

Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival.

Manapov F, Klöcking S, Niyazi M, Levitskiy V, Belka C, Hildebrandt G, Fietkau R, Klautke G.

J Neurooncol. 2012 Sep;109(2):309-14. doi: 10.1007/s11060-012-0894-4. Epub 2012 May 20.

PMID:
22610939

Supplemental Content

Support Center